Research Triangle Park, N.C., July 15, 2008 – Life sciences company Entegrion continues to strengthen its leadership team with the addition of Michael Galiger, its new manufacturing and engineering manager. Galiger has more than 10 years of experience in medical and consumer products industries. At Entegrion, Galiger will be focused on product scale up, technology transfer and regulatory controls.
“We are already benefiting from Michael’s exceptional experience in international management and engineering within the medical device industry,” said Stan Eskridge, Entegrion’s president and CEO.
Prior to joining Entegrion, Galiger served as the director of new product development and strategic sourcing at Charter Medical where he worked for nearly 4 years. There, Galiger successfully helped the company recover from an FDA warning letter and refocus the new product development pipeline to match the company’s core competencies.
Before working at Charter Medical, Galiger served as an engineer at Depuy Mitek, a leader in the medical device segment of surgical sports medicine, where he was involved in new products and international manufacturing start up. Galiger has also served as a plant engineer at International Paper.
Galiger received his bachelor of business administration from Kennesaw State University and his bachelor of industrial engineering from Georgia Institute of Technology.
About Entegrion
Entegrion is a life sciences company that selectively integrates synergistic technologies with those in its patent portfolio for development of novel devices and drugs for hemorrhage control, resuscitation, and associated tissue repair. The company is based in North Carolina’s Research Triangle Park, and is the inventor of StasilonTM – the FDA cleared hemostatic medical textile technology cleared for use by prescription and also by consumers – from which multiple hemorrhage control products are being made. Building upon technologies licensed from the University of North Carolina, Entegrion’s portfolio includes platelet-derived platform technologies that are being developed as topical gels and sprays for tissue repair, infusible hemostatic agents for the control of internal hemorrhage, and novel vehicles for delivery of drugs to targeted tumors and other sites of internal bleeding. For more information, visit www.entegrion.com.
